Sarepta Therapeutics Inc (NASDAQ:SRPT)‘s stock had its “buy” rating reiterated by equities research analysts at Royal Bank Of Canada in a research note issued on Tuesday. They currently have a $64.00 price objective on the biotechnology company’s stock. Royal Bank Of Canada’s price objective suggests a potential upside of 29.16% from the stock’s previous close.

A number of other equities analysts also recently weighed in on the company. Janney Montgomery Scott upped their target price on Sarepta Therapeutics from $65.00 to $73.00 and gave the company a “fair value” rating in a report on Monday, July 24th. Credit Suisse Group increased their price target on shares of Sarepta Therapeutics from $5.65 to $81.00 and gave the stock an “outperform” rating in a research report on Thursday, September 7th. Nomura restated a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, September 5th. Needham & Company LLC restated a “buy” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, September 6th. Finally, Zacks Investment Research downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and fifteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $62.79.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 49.55 on Tuesday. The stock’s market capitalization is $3.19 billion. The company has a 50-day moving average of $42.14 and a 200-day moving average of $35.85. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $63.03.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.46. The business had revenue of $35.01 million for the quarter, compared to the consensus estimate of $22.52 million. Sarepta Therapeutics had a negative return on equity of 62.68% and a negative net margin of 180.07%. Sarepta Therapeutics’s revenue for the quarter was up 350000.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.19) earnings per share. Equities analysts expect that Sarepta Therapeutics will post ($1.22) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Sarepta Therapeutics’ (SRPT) Buy Rating Reiterated at Royal Bank Of Canada” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/sarepta-therapeutics-srpt-buy-rating-reiterated-at-royal-bank-of-canada/1604129.html.

In other Sarepta Therapeutics news, CEO Douglas S. Ingram purchased 47,058 shares of the business’s stock in a transaction dated Thursday, July 27th. The stock was bought at an average cost of $42.50 per share, for a total transaction of $1,999,965.00. Following the completion of the acquisition, the chief executive officer now directly owns 382,058 shares in the company, valued at $16,237,465. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Shamim Ruff sold 12,138 shares of the company’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $42.97, for a total value of $521,569.86. Following the transaction, the senior vice president now owns 27,312 shares of the company’s stock, valued at $1,173,596.64. The disclosure for this sale can be found here. Insiders have sold 78,056 shares of company stock valued at $3,224,208 over the last 90 days. Corporate insiders own 9.60% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. grew its stake in shares of Sarepta Therapeutics by 4,403.1% in the first quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock worth $156,664,000 after acquiring an additional 5,175,193 shares during the last quarter. Vanguard Group Inc. increased its position in Sarepta Therapeutics by 4.0% during the second quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after acquiring an additional 162,543 shares during the period. State Street Corp increased its position in Sarepta Therapeutics by 21.2% during the first quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock worth $94,641,000 after acquiring an additional 559,342 shares during the period. HealthCor Management L.P. increased its position in Sarepta Therapeutics by 31.1% during the second quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after acquiring an additional 481,890 shares during the period. Finally, Camber Capital Management LLC bought a new position in Sarepta Therapeutics during the first quarter worth $39,960,000. 65.41% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.